Loading
NKG2A is the brake on NK cells and some killer T cells that is pressed by HLA-E, a molecule tumours raise to look like self. Monalizumab blocks it and is in phase 3 with durvalumab in lung cancer and with cetuximab in head and neck cancer.
KLRC1 (chromosome 12p13.2) encodes NKG2A, which pairs with CD94 (KLRD1) on cytotoxic and regulatory lymphocytes and recognises the non-classical class Ib molecule HLA-E loaded with signal-sequence peptides from classical class Ia molecules, letting cytotoxic cells monitor MHC class I on healthy cells and tolerate them (UniProt P26715). It is predominantly expressed on NK cells and on subsets of intraepithelial, gamma-delta and memory CD8 T cells (protein level). Monalizumab, an anti-NKG2A antibody, is in the PACIFIC-9 phase 3 study with durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer (NCT05221840) and the INTERLINK-1 phase 3 with cetuximab in head and neck squamous cell carcinoma (NCT04590963).
In plain words · NKG2A is the brake on NK cells and some killer T cells that is pressed by HLA-E, a molecule tumours raise to look like self. Monalizumab blocks it and is in phase 3 with durvalumab in lung cancer and with cetuximab in head and neck cancer.
NKG2A is the brake on NK cells and some killer T cells that is pressed by HLA-E, a molecule tumours raise to look like self. Monalizumab blocks it and is in phase 3 with durvalumab in lung cancer and with cetuximab in head and neck cancer.
A C-type lectin-like inhibitory receptor; the CD94/NKG2A heterodimer reads HLA-E and signals through ITIMs.
No product in this corpus aims at NKG2A (KLRC1) yet. Checkpoint drugs are antibodies that cover one side of an immune ‘stand down’ handshake so T cells stay active.
First described 1991. Earliest sequence paper UniProt cites for the protein: Houchins J.P. et al, J. Exp. Med, 1991, "DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells". Source.
Sources: HGNC HGNC:6374 (approved symbol, name, aliases and cross-references); UniProt P26715 (protein name, function and tissue specificity)
A C-type lectin-like inhibitory receptor; the CD94/NKG2A heterodimer reads HLA-E and signals through ITIMs.
Query for this target: (TITLE:"NKG2A" OR ABSTRACT:"NKG2A" OR TITLE:"KLRC1" OR ABSTRACT:"KLRC1" OR TITLE:"NKG2-A" OR ABSTRACT:"NKG2-A" OR TITLE:"CD159a" OR ABSTRACT:"CD159a" OR TITLE:"killer cell lectin like receptor C1" OR ABSTRACT:"killer cell lectin like receptor C1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NKG2A (KLRC1), not a curated reading list.
Shares Checkpoint (two meanings), The cancer-immunity cycle, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle, Non-small-cell lung cancer and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle, Immune checkpoint inhibitors and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle and the tag checkpoint-map.